Revance Therapeutics Inc (NASDAQ:RVNC) shares, rose in value, with the stock price down by -3.08% to the previous day’s close as strong demand from buyers drove the stock to $4.41.
Actively observing the price movement in the last trading, the stock closed the session at $4.55. The value of beta (5-year monthly) was 1.09. Referring to stock’s 52-week performance, its high was $37.98, and the low was $4.37. On the whole, RVNC has fluctuated by -32.15% over the past month.
With the market capitalization of Revance Therapeutics Inc currently standing at about $459.61 million, investors are eagerly awaiting this quarter’s results, scheduled for May 06, 2024 – May 21, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.75, which is expected to increase to -$0.46 for fiscal year -$2.3 and then to about -$1.06 by fiscal year 2025. Data indicates that the EPS growth is expected to be 39.90% in 2025, while the next year’s EPS growth is forecast to be 53.90%.
Analysts have estimated the company’s revenue for the quarter at $56.63 million, with a low estimate of $53.47 million and a high estimate of $59.6 million. According to the average forecast, sales growth in current quarter could jump up 14.80%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $281.72 million, representing an increase of 20.40% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that RVNC’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of RVNC currently trading nearly -16.64% and -20.51% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 34.89, while the 7-day volatility ratio is showing 5.74% which for the 30-day chart, stands at 6.89%. Furthermore, Revance Therapeutics Inc (RVNC)’s beta value is 1.09, and its average true range (ATR) is 0.39.
A comparison of Revance Therapeutics Inc (RVNC) with its peers suggests the former has fared considerably weaker in the market. RVNC showed an intraday change of -3.08% in last session, and over the past year, it shrunk by -86.95%%.
Data on historical trading for Revance Therapeutics Inc (NASDAQ:RVNC) indicates that the trading volumes over the past 10 days have averaged 1.37 million and over the past 3 months, they’ve averaged 1.83 million. According to company’s latest data on outstanding shares, there are 104.22 million shares outstanding.
Nearly 10.25% of Revance Therapeutics Inc’s shares belong to company insiders and institutional investors own 75.38% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 10.87 million shares as on Mar 15, 2024, resulting in a short ratio of 4.95. According to the data, the short interest in Revance Therapeutics Inc (RVNC) stood at 10.43% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 12.34 million. The stock has fallen by -49.83% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RVNC stock heading into the next quarter.
